New coumarin-piperazine derivatives alleviate inflammatory bowel diseases as IL-6 inhibitors by targeting NF-κB pathway

Technical Summary: New Coumarin-Piperazine Derivatives as IL-6 Inhibitors Targeting the NF-κB Pathway for IBD Treatment

Problem Statement
Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis (UC), is a chronic, difficult-to-cure intestinal disorder characterized by immune dysregulation and inflammation. Current therapeutic strategies, including aminosalicylates, glucocorticoids, and biologics, often face limitations regarding efficacy, side effects, or the lack of a definitive cure. The pathogenesis involves the overactivation of the nuclear factor kappa-B (NF-κB) pathway and the subsequent upregulation of pro-inflammatory cytokines, particularly Interleukin-6 (IL-6). While IL-6 inhibitors and NF-κB pathway modulators represent promising therapeutic targets, there is a continued need for novel small-molecule agents with high selectivity and low toxicity to effectively manage IBD.

Methodology
The study employed a rational drug design approach to synthesize and evaluate a series of new coumarin-piperazine derivatives.

• Synthesis: A concise synthetic route was established starting from 4-hydroxycoumarin. Key steps included the conversion to 4-bromocoumarin, substitution with 1-(2-N-Boc-aminoethyl)piperazine, deprotection of the Boc group, and subsequent sulfonylation with various sulfonyl chlorides to yield compounds 4a–4t.
• In Vitro Screening: The anti-inflammatory potential of the derivatives was assessed using an LPS-induced RAW264.7 macrophage model. Nitric oxide (NO) production was measured as the primary indicator of anti-inflammatory activity, with dexamethasone serving as the positive control. Cytotoxicity was evaluated via the MTT assay.
• In Vivo Efficacy: The most potent compound, 4s, was selected for in vivo evaluation using a dextran sulfate sodium (DSS)-induced ulcerative colitis mouse model. Efficacy was measured through body weight monitoring, Disease Activity Index (DAI) scoring, colon length assessment, and histological examination (H&E staining) of colon tissue.
• Safety and Mechanism: Systemic toxicity was evaluated via H&E staining of major organs (heart, liver, spleen, lung, kidney). The molecular mechanism was investigated using quantitative PCR (qPCR) to analyze the mRNA expression levels of key inflammatory markers (IL-6, IL-1β, IL-10) and NF-κB pathway components (Rela/p65, IKKβ, IκBα) in colon tissues.

Key Contributions and Results

• Synthesis and SAR: A library of 20 coumarin-piperazine derivatives was successfully synthesized with yields ranging from 60% to 84%. Structure-activity relationship (SAR) analysis revealed that aryl sulfonamides generally exhibited superior NO inhibition compared to aliphatic sulfonamides. Specific substituents, such as CF₃, OCH₃, Cl, t-Bu, and Br, enhanced activity, while F, NHAc, and NO₂ groups tended to reduce it.
• In Vitro Potency: Several compounds demonstrated excellent inhibition of NO generation with IC₅₀ values below 12 μM. Compound 4s (2-naphthyl sulfonamide derivative) emerged as the most potent candidate with an IC₅₀ of 3.67 μM, outperforming the positive control dexamethasone (IC₅₀ = 8.63 μM).
• In Vivo Efficacy: In the DSS-induced UC mouse model, compound 4s significantly alleviated inflammatory injury. Notably, the low-dose group (6.25 mg/kg) showed a more pronounced recovery in body weight and a better restoration of normal metabolic states compared to the high-dose group (12.5 mg/kg). While colon length did not differ significantly from the model group, histological analysis confirmed that 4s effectively repaired colonic tissue, reduced inflammatory cell infiltration, and restored crypt structure, with the low-dose group showing the most significant tissue repair.
• Safety Profile: Comprehensive organ toxicity assessments indicated that compound 4s exhibited no obvious systemic toxicity. Gross morphology and histological examinations of the heart, liver, spleen, lung, and kidney revealed no pathological damage or drug-induced lesions.
• Mechanism of Action: Mechanistic studies demonstrated that 4s significantly downregulated the mRNA expression of pro-inflammatory factors IL-6 and IL-1β while modulating the NF-κB pathway. Specifically, 4s reduced the expression of key regulatory molecules including IL-6, IKKβ, and IκBα in colon tissue. This suggests that the compound exerts its therapeutic effect by inhibiting the IL-6/NF-κB signaling axis, thereby interrupting the cascade of chronic intestinal inflammation.

Significance
The authors claim that this work successfully identifies a new class of coumarin-piperazine derivatives as potent anti-inflammatory agents for IBD treatment. The study highlights compound 4s as a promising lead candidate that effectively alleviates intestinal inflammation in a UC model without causing systemic toxicity. By demonstrating that these derivatives function as IL-6 inhibitors targeting the NF-κB pathway, the research provides a mechanistic basis for the development of novel, small-molecule therapeutics for IBD that offer high efficacy and a favorable safety profile. The findings support the potential of targeting the IL-6/NF-κB axis as a viable strategy for managing chronic intestinal inflammation.